

Australian and New Zealand SOCIETY FOR IMMUNOLOGY INC.



# PROGRAM

2022 ADVANCED IMMUNOLOGY SCHOOL

IMMUNE CHALLENC

17-20 MAY 2022

#### **Platinum Sponsor**







science



BioLegend



#### **Supporting Sponsors**

MONASH BIOMEDICINE DISCOVERY INSTITUTE











## **CONTENTS**

WELCOME	3
CODE OF CONDUCT	4
ABOUT ASI	7
AIS FACULTY	8
PROGRAM OVERVIEW	18
PARTICIPANT SESSIONS	20
SHORT TALK ABSTRACTS	21
SPONSORS	
ORGANISING & DELEGATE SUB COMMITTEES	45

## WELCOME TO ASI-2

We warmly welcome you to the 2nd Advanced Immunology School, here at Longpoint Conference Centre Sydney. We meet on the traditional country of the Darug nation and pay our respects to their Elders past, present and emerging.

The goal of ASI Advanced Immunology School is to immerse selected early career researchers in cutting-edge basic and clinical immunological research in a friendly environment. This 4-day course will combine presentations from experts in the field and round-table discussions, providing an in-depth view of state-of-the-art advances and emerging themes in immunology. The theme of this AIS is 'Immune Challenges'. Speakers expertise ranges from autoimmunity, infection control, innate and adaptive immunity and cancer immunology. There will also be a technical talk focusing on state-of-theart single cell technologies.

Further training and career development opportunities are provided in the form of workshops, which will focus on grant and paper writing and careers in science.

There are also many opportunities to relax and interact with the teaching faculty and delegates, which we hope will foster new collaborations and professional networks. The aim of this school is to engage, interact, learn and enjoy and there will be prizes for outstanding contributions by the delegates, so don't be shy. We encourage social media! Post to our tag @ASImmunology on facebook and use #ASIAdvImmSchool on Twitter when sharing with your friends and colleagues back in the lab.

We anticipate the AIS will be an enjoyable and enriching experience that will equip you with skills, ideas and networks that you can apply immediately in your research and memories for years to come. Most importantly, we hope you have a fun and enjoyable time and that you'll leave with a new level of excitement about the part of our body that is so important to our health, the all-amazing immune system!

We thank you once again for your interest in the Advanced Immunology School and we are really looking forward to connecting with you over the coming days!

With warm regards,

Susanne Heinzel, Joanne Reed, Tyani Chan, Ee Shan Pang, Debbie Burnett The ASI-AIS-2 Organising Committee

## **CODE** OF CONDUCT

## **MEMBERS CONDUCT**

An appropriate standard of professional conduct is expected from members at all ASI meetings and events. Concerns about breeches of this conduct should be brought to the immediate attention of a member of the meeting organising committee or society executive.

## SOCIAL MEDIA ETIQUETTE

Whilst we encourage engagement on social media from attendees we realise that sharing unpublished results without speakers' consent may compromise the ability to publish in scientific journals in the future and/or progress of the research.

We therefore ask attendees to:

- » Refrain from recording and/ or reproducing audio, video or photos from oral presentations unless explicit permission is granted from the presenter
- » Communicate across social media platforms in a respectful manner

## DO

- » Keep phones on silent during sessions!
- » Post to our tag @ASImmunology on facebook and use #ASIAdvImmSchool on Twitter when sharing with your friends and colleagues back in the lab.
- » Enjoy making new connections at the meeting and communicate in a respectful manner

## DON'T

» Post any photos of others' primary data

## **DISCLAIMER OF LIABILITY**

The Organising Committee will not accept liability for damages of any nature sustained by participants or their accompanying persons or loss of or damage to their personal property as a result of the meeting or related events.

Comprehensive Solutions to Uncover What Makes Each Cell Unique

## Protein Detection by Sequencing with TotalSeq<sup>™</sup> Reagents

Multiomics has transformed traditional sequencing experiments by providing unparalleled protein and genetic analysis on a single-cell basis. Discover our comprehensive and unique products, including antibodies, panels, and hashtag reagents, that integrate seamlessly into existing workflows to push the boundaries of sequencing.

#### Explore TotalSeq<sup>™</sup> Solutions, including:

- Pre-optimized antibody cocktails to characterize cells to an unprecedented depth
- Free, cloud-based Multiomics Analysis Software to easily explore data without needing a bioinformatics background
- The largest selection of reliable antibody clones compatible with a variety of single-cell platforms
- Hashtag reagents to enable sample multiplexing and increase efficiency



Learn More: biolegend.com/totalseg

#### Characterize Cellular Diversity



Clustering of 5,000 CITE-seq single-cell expression profiles of PBMCs reveals distinct cell populations based on transcriptome analysis. The panel shows global gene expression relationships among all cells, and major cell types separated based on gene expression.





BioLegend products are manufactured in an ISO 13485:2016certified facility to ensure the highest quality standards. biolegend.com

World-Class Quality | Superior Customer Support | Outstanding Value

## **COVID SAFE** PROCEDURES

The ASI Advanced Immunology School require that all attendees:

- » Are fully-immunised (including booster) against COVID-19.
- » Provide proof of a negative RAT taken on the morning of the school as a condition of entry.
- Comply with the venue, Long
  Point Conference Centre COVID
  safe plan and current NSW
  Health COVID legislation.
- » We ask all attendees to take another RAT (provided) on day 2 of the AIS.

All attendees will be provided with a N95/P2 mask on arrival, which they are encouraged to wear when social distancing is not possible.

In the event an attendee at the school tests positive to COVID-19 they will

be asked to follow the NSW COVID policy and legislation, which at the moment requires immediate isolation. AIS organisers must be contacted immediately to allow identification of close contacts. Please note that unfortunately the AIS cannot provide isolation accommodation for attendees who test positive to COVID-19 prior to or during the school and will not be responsible for any costs incurred for accommodation or travel due to requirements to isolate. As such, if you test positive prior to or during the school it will be your responsibility to source your own isolation accommodation and relevant pathways home. For more information on ASI's COVID-19 event policy please refer to:

https://www.immunology.org.au/ News-Events/event-policy/

# **ABOUT** ASI

The Australian and New Zealand Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region.

It is a broadly-based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The ASI provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.





#### www.MedChemExpress.com

#### Inhibitors Screening Libraries Proteins

#### Inhibitors & Agonists

30,000+ Specific

spots areas of biology, medicine and

#### Life Science Products

1,900+ Bioactive Peptides

400+ Ion Indicators, ROS/NO Probes, etc.

Inhibitory Antibodies

CCK-8, Magnetic Beads, Inhibitor Cocktails, etc.

#### Recombinant Proteins

**GMP-grade** Proteins

#### Drug Discovery

#### Customized Services

Peptide Synthesis Customized Service

**PROTAC-Related** 

#### Top Publications Citing of MCF Products



#### MedChemExpress USA

Tel: 609-228-6898 E-mail: sales@MedChemExpress.com Fax: 609-228-5909 Tech Support: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

MedChemExpress Australia

E-mail: au.sales@MedChemExpress.com Tech Support: tech@MedChemExpress.com





DS

MCE Global Partners

Takeda Lilly Roche









U NOVARTIS

# **AIS** FACULTY

## VANESSA BRYANT Walter and Eliza Hall Institute



Dr Vanessa Bryant's research aims to solve the underlying genomic and functional causes of rare disorders of the immune system, focusing on the variable disorder Common Variable Immunodeficiency (CVID), both as a primary immunodeficiency in itself, and as a model for other complex immune disorders. Dr Bryant's research combines functional genomics with quantitative immunology to transform the way we approach and treat rare and complex immune diseases. Her research has identified novel CVID genes and mutations responsible for disease, including discovery NFkappaB1 deficiency, now recognised as the largest monogenic cause of CVID. This discovery has greatly

accelerated diagnoses for patients worldwide, facilitating early access to treatment to avoid significant complications of untreated and unmanaged disease.

Dr Bryant is the inaugural Sir Clive McPherson Family Research Fellow and a Royal Melbourne Hospital DW Keir Fellow. She is a Laboratory Head in the Immunology Division at the Walter and Eliza Hall Institute and Clinical Scientist at The Royal Melbourne Hospital. Vanessa completed her PhD in immunology at the Garvan Institute of Medical Research in Sydney with Prof. Stuart Tangye, before performing her postdoctoral research with Prof. Jean-Laurent Casanova at The Rockefeller University in New York.

Dr Bryant leads clinical genomics programs aimed to implement early, accurate gene-based diagnoses for people with suspected rare primary immunodeficiency to allow early and targeted care and avoid the complications of unmanaged disease. Dr Bryant also co-leads COVID PROFILE, a longitudinal clinical study of immunity to COVID-19.

### KATE SCHRODER University of Queensland



Professor Kate Schroder heads the Inflammasome Laboratory at the Institute for Molecular Bioscience (IMB), University of Queensland, as an NHMRC RD Wright Fellow. She is also the Director of the IMB Centre for Inflammation and Disease Research, the Chair of the IMB Diversity and Inclusion Committee.

Kate's graduate studies with Prof David Hume defined novel macrophage activation mechanisms, and her PhD was awarded in 2005. Her subsequent postdoctoral research with Profs Hume and Sweet identified surprising inter-species divergence in the inflammatory programs of human versus mouse macrophages (PNAS USA, 2012). As an NHMRC CJ Martin Fellow

in Switzerland, Kate then trained with Prof Jürg Tschopp, a pioneer in the fields of inflammasome and cell death signalling pathways. Kate returned to Australia, and was appointed an IMB Lab Head in 2013. Kate's laboratory investigates the molecular mechanisms governing inflammasome activity and caspase activation, the cell biology of inflammation, cell death and host defence, and mechanisms of inflammasome inhibition by cellular pathways and new small molecule inhibitors. UQ start-up company, Inflazome (recently bought by Roche) is posed to start Phase 2 human clinical trials of these compounds as novel anti-inflammatory therapeutics. Kate served on the Inflazome Scientific Advisory Board from 2016-2017.

#### **CHRISTIAN ENGWERDA**

#### **QIMR Berghofer Medical Research Institute**



Christian Engwerda studies the behaviour of T cells during parasitic infections with a particular focus on understanding how T cells are controlled. His group works with experimental models of malaria and leishmaniasis, and in recent years, have increasingly concentrated on studying samples from volunteers deliberately infected with parasites, as well as from malaria and leishmaniasis patients. The goal of their research is to improve anti-parasitic immunity using host-directed treatments in combination with vaccines and/or anti-parasitic drugs. They also use their discoveries in parasitic diseases to guide development of new treatments for chronic inflammatory conditions.

### **KATHERINE KEDZIERSKA**

#### Peter Doherty Institute for Infection and Immunity



Katherine received her PhD from Monash University in 2002 for her studies on the mechanisms underlying defective immune functions after HIV infection. Her PhD work was recognised by the 2001 Premier's Commendation for Medical Research, 2002 Monash University Mollie Holman Doctoral Medal and an NHMRC Peter Doherty Postdoctoral Fellowship to pursue her postdoctoral research with Laureate Professor Peter Doherty at University of Melbourne. Her postdoctoral work was focused on the early establishment of influenza-specific CD8+ T cell memory, TCR repertoire diversity and viral escape in a mouse model of influenza virus infection. In 2007, she got awarded an NHMRC RD

Wright Fellowship and grant funding to establish her own research team.

She is currently an NHMRC Investigator Fellow and a group leader of 'Human T cell Laboratory' in Department of Microbiology and Immunology at University of Melbourne. Her research interests include human T cell immunity to pandemic, seasonal and newly emerged influenza viruses, anti-viral immunity in the young, the elderly and Indigenous Australians, viral escape and generation of immunological memory in human influenza infection. She also studies human immunity to SARS-CoV2 in COVID-19 patients.

Katherine is a recipient of a number of prestigious awards, including 2016 Australian Academy of Science Jacque Miller Medal, 2011 NHMRC Excellence Award and 2011 Scopus Young Researcher of the Year Award. She is a Co-Head of Indigenous Health at the Doherty Institute. In 2019, she was elected as a Fellow of the Australian Academy of Health and Medical Science (AAHMS).

### **ANSELM ENDERS** The John Curtin School of Medical Research



Anselm Enders is interested in human primary immunodeficiency diseases (PIDs) and what they can teach us about the development and function of the immune system in general and particularly B cells.

He studied medicine at the University of Freiburg, Germany. As an undergraduate student he spent one year at the WEHI in the group of Andreas Strasser to study the role of Bim in the negative selection of B cells before returning to Germany to finish his medical studies and start training in Paediatric Immunology. In 2005 he returned to Australia for postdoctoral studies in Chris Goodnow's laboratory at ANU. Since 2012 he has his own group at ANU centred around understanding novel

genes crucial for B cell development and the molecular pathogenesis of PIDs through the analysis of mouse models. Recently his interest is focused on understanding how PID causing mutations not only impair the development or function of immune cells but frequently also cause haematological malignancies.

#### SUSANNE HEINZEL Walter and Eliza Hall Institute



Dr Susanne Heinzel is a cellular immunologist at the Walter and Eliza Hall Institute for Medical Research in Melbourne. Her work focuses on the quantitative analysis of the rules that govern the activation, survival and differentiation of T and B lymphocytes in health and disease. She is interested to understand the signal integration and regulation of cell fate decisions in lymphocytes. She has discovered the role of the oncogene Myc as a 'division timer' in healthy lymphocytes. Her recent work has been published in journals such as Science, Nat Immunology, Nat Comms, JI and PNAS. She is the founder of the ASI-AIS and was president of the ASI 2017-2018.

### **ROSLYN KEMP** University of Otago

I am a researcher studying the immune responses of the gut, with a special focus on T cells and myeloid cells in people with colorectal cancer and inflammatory bowel disease. I did my PhD with Franca Ronchese at the Malaghan Institute of



Medical Research, and then postdocs in USA and UK with Dick Dutton and Ben Seddon. I was appointed to an academic role at the University of Otago in 2009. My experience has always been in T cell biology, and since establishing my lab at Otago, I have tried to incorporate fundamental immunology experiments and approaches into the clinical immunology research world. I have tried to incorporate the newest technologies into my research design wherever possible, despite the financial and practical limitations in New Zealand.

I teach all undergraduate levels of students, and supervise Hons, MSc and PhD students. My lab is designed to be a collaborative and supportive

environment, where all members help each other, in both lab work as well as analysis. I value the chance for my students to present their own work as much as possible, and this has been obviously problematic since March 2020. My teaching philosophy is to teach students to be scientists, rather than to teach them science. In 2015, I was awarded an Ako Aotearoa Award for National Tertiary Teaching Excellence, which recognised the success of my teaching approach. Immunology is incredibly complicated, but my teaching and my research both celebrate this complexity, and we try to understand everything all together, rather than focusing on one or two specific things at a time. Not always possible, but definitely always fun.

### MICHELLE WYKES Queensland Instittue of Medical Research



Associate Professor Michelle Wykes is Group Leader of the Molecular Immunology Laboratory at the QIMR Berghofer. She is an expert on "immune checkpoints" which are the basis for a new type of cancer treatment known as "immunotherapy". Her research in "immune checkpoints" started when she was looking for the reason Plasmodium spp, which cause malaria, could evade immunity.

Her laboratory initially discovered Programmed cell death1 Ligand 2 (PD-L2) was contrary to dogma, not a "brake" on the immune system, but actually an essential activator of immunity. In 2014, they identified the second "activating" receptor for PD-L2 and with

an NHMRC development grant (2016-2018) funding made fully human therapeutic antibodies to this target which were licensed to Merck KGaA in 2020. In 2019, she was awarded a second NHMRC development grant (2019-2021) to develop a novel immune biologic and in 2020 awarded 1 of only 3 Australia/NZ CSL Research Accelerator Initiative prizes to advance her novel immune inhibitor in collaboration with CSL.

#### LISA EBERT University of South Australia



Dr Lisa Ebert has spent over 20 years researching the immune system, cancer, and interactions between the two. She completed her PhD in 2002 at the University of Adelaide, and then undertook postdoctoral research positions at the University of Bern in Switzerland (2002 – 2005) and at the Ludwig Institute for Cancer Research in Melbourne (2005 – 2010). During this time, she developed a focus on understanding how the immune system interacts with cancer, and using this knowledge to develop and improve cancer immunotherapies. In 2011, she returned to Adelaide as Senior Research Fellow at the Centre for Cancer Biology – a unique alliance between the South Australian public health

system and the University of South Australia. Her current research is focussed on developing CAR-T cell therapies for brain cancer, and identifying key factors which determine the success of checkpoint blockade immunotherapies in melanoma patients. These studies are conducted at the interface between laboratory and clinic, with close ties to the Royal Adelaide Hospital Cancer Clinical Trials Unit.

#### MICHAELA LUCAS University of Western Australia



Clinical Professor Michaela Lucas is an Immunologist/ Immunopathologist and Clinician-Scientist with appointments at Sir Charles Gairdner Hospital (SCGH), the Perth Children's Hospital, and The University of Western Australia, where she leads a multi-disciplinary team of clinical and basic science researchers, microsurgeons and technicians, at the Immunology and Transplantation Lab. Following medical training in Germany, she completed a Marie Curie Research Fellowship and postdoctoral position at the University of Oxford where she studied liver T-cell immunology. Her research interests and expertise now span T cell immunology including the pathogenesis of T cell

mediated drug allergies, anti-viral T cell responses, vaccine development, and most recently understanding the role of inflammation in the development of adaptive immunity in organ transplantation.

Professor Lucas's research has produced over 100 peer-reviewed papers. She has held multiple NHMRC and ACH2 grants as a principle and co-investigator, and has led investigator-driven randomised controlled trials in antibiotic allergy, as well as serving as Principal Investigator at the SCGH site for the multi-centre BRACE Trial, investigating the BCG vaccination to reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure. She is a leading clinician in the field of Drug Allergy in Australia having established national guidelines in drug allergy management. She is the President of the Australasian Society of Immunology and Allergy (ASCIA), Chair of the ASCIA Drug Allergy Committee, and the project lead in Drug Allergy for the National Allergy Strategy. She consults for the Australian Digital Health Agency on the My Health Record initiative and the Australian Health and Safety Agency on drug allergy documentation. In addition, she participates in the National Organ Transplantation Service, and is a clinical expert on immunosuppression, including the use of novel biological agents and routine immunosuppressive medications.

### IAIN COMERFORD Adelaide University



Dr Comerford completed his Ph.D. in chemokine biology and immunology at the Beatson Institute for Cancer Research and the University of Glasgow with Professor Robert Nibbs in 2005. He then joined the Chemokine Biology Laboratory at the University of Adelaide with Professor Shaun McColl, focussing on regulation of the immune system by atypical chemokine receptors. Since then, he has been the recipient of fellowships and project grant funding from MS Research Australia, holds project grant funding from the Cancer Council SA, the NHMRC and is a research fellow & lecturer in the School of Biological Sciences at the University of Adelaide and co-leads the Chemokine Biology Laboratory.

His current research interests are in the regulation of T cells during the resolution of inflammation during infection and autoimmunity; the migration of T cells into solid tumours; and the role of atypical chemokine receptors in shaping functional chemokine gradients.

#### SHALIN NAIK Walter and Eliza Hall Institute



Dr Naik is a graduate of the University of QLD (Microbiology & Biochemistry) where he did Honours with Prof. David Hume on macrophage activation by CpG DNA. After a 2-year hiatus in London, he returned to Melbourne to do his PhD with Prof. Ken Shortman on dendritic cell development at WEHI. It was here he gained an interest in single cell tracking and fate determination in biology and was awarded his PhD in 2006. Interested in the emerging technology of 'cellular barcoding' Dr Naik did his postdoc in the laboratory of Prof. Ton Schumacher at the Netherlands Cancer Institute, where he traced the single cell output of haematopoietic stem and

progenitor cells in vivo. After returning to WEHI in 2013, he was later appointed as a Laboratory Head in the Immunology Division where his lab uses single cell systems biology to investigate immunology, cancer and development. He also setup and led the Single Cell Open Research Endeavour (SCORE) at WEHI – a collaborative centre for single cell technology, experimental design and computational projects.

#### **GEORGINA CLARK** University of Sydney



A/Professor Georgina Clark started research life as a molecular immunologist with an interest in leucocyte surface molecules and antibody engineering. She was awarded her PhD from the University of Melbourne, completed postdoctoral studies at Oxford University and has worked at the Christchurch Medical School, University of Otago, Mater Medical Research Institute, ANZAC Research Institute and the University of Sydney. Her research spans studies in human and mouse biology allowing a focus on translational research from mouse to human then bench to commercialisation to enable progression to first in human trials. Her work led her to chair the Human Leucocyte Differentiation Council

which is the peak body for nomenclature and validation of antibodies to human leucocyte membrane molecules. A/Prof Clark heads Dendritic Cell Research at the ANZAC Research Institute where she is also currently acting in the Director role.

The cell surface molecules that are of interest to A/Prof Clark are those expressed by human dendritic and myeloid cells, and to which antibodies can be developed as immune therapies for cancer. Together, Dendritic Cell Research has developed a human anti-human CD83 antibody as a novel immunosuppressive agent which has been spun out into a biotech start-up, Kira Biotech Pty Ltd to progress commercialisation towards first in human trials and beyond. The group continues to develop humanised antibodies targeting CD300 molecules as therapeutics for acute myeloid leukemia and novel phagocytic checkpoints to induce anti-tumour responses to cancer.

#### **CONNIE JACKAMAN** Curtin Unviersity



Dr Connie Jackaman works on ageing and innate immune responses and is currently based at Curtin Health Innovation Research Institute (CHIRI), Curtin University, Western Australia. She completed her PhD in tumour immunology, followed by postdoctoral training in muscle pathology and related diseases. She moved to CHIRI, Curtin University in 2012 and leads the Immunoageing Lab investigating myeloid cell function in the elderly. Her current research is focussed on examining the impact of dysregulated myeloid cell inflammation on age-related diseases/comorbidities, including musculoskeletal injury/ muscle diseases, dementia and cancer.

#### JOANNE REED Westmead Institute for Medical Research



Joanne Reed is a Group Leader at the Westmead Institute, Adjunct Associate Professor at University of Sydney and Co-Chair of ASI's Advanced Immunology School. She has a long-standing interest in autoimmune disease, particularly the origins and pathogenesis of autoantibodies. Joanne completed her PhD at Flinders University, Adelaide in 2009, studying Sjogren's syndrome and lupus. She was then awarded an NHMRC CJ Martin Fellowship for postdoctoral training at New York University, where she worked on neonatal lupus. In 2013 she returned to Australia to develop genomic technology to study autoimmunity at Australian National University and the Garvan Institute. In 2021,

Joanne established her own lab at the Westmead Institute. Her team has developed single cell genomic approaches to study patient B cells responsible for severe autoimmune pathology, with the goal of identifying targeted therapies.

### **ANDY FLIES** Menzies Institute of Medical Research



Andrew Flies completed a BSc at Minnesota State University, Mankato in 2002, with minors in Chemistry and Math. He then transitioned to immunology and worked at The Mayo Clinic (2003-2004) and Johns Hopkins University (2004-2006) where his primary responsibility was developing and testing monoclonal antibodies for mouse cancer models and in vitro human assays. He earned his PhD from Michigan State University in Dec 2012. His research studied the effects of ecology on the immune system of a large carnivore and spent nearly a year living in a tent in the Maasia Mara, Kenya to collect behavioural observations and biological samples. He moved to Australia in 2013 and

worked on vaccinia-virus based vaccines until winning a postdoctoral fellowship for Tasmanian devil immunology. His focus since 2014 has been on the development of vaccines and reagent development (e.g. recombinant proteins, antibodies) for nonmodel species. His recent publications focus on an adenovirus-based cancer vaccine (Expert Review of Vaccines, 2020), rapid immunology reagent development (Science Advances, 2020), "Rewilding immunology (Science, 2020), and regulation immune evasion by cancer cells (Journal of Cancer Research and Clinical Oncology, 2021).

# PROGRAM



#### BREAKFAST

9.00-10.30 Faculty Session II Chair: Emily Bryan

9.00-9.45 Vanessa Bryant

9.45-10.30 Michaela Lucas

10:30-11:00 BREAK

**11.00-12.30 Participant session II** Chair: Yanran Zhao

12:30-13:30 LUNCH

**13.30-15.00 Faculty Session III** Chair: Sarah Dart

13.30-14.15 Ros Kemp

14.15-15.00 Kate Schroder

15:00-15:30 BREAK

**15.30-16.30 Participant session III** Chair: Madeleine Wemyss

16.30-16.35 Australian Biosearch/BioLegend

16.45- 18.15 Professional skills workshop

Strategically advance your scientific career. S Heinzel, M Lucas, R. Kemp

18.30 - 19.30 DINNER

19.30 - SOCIAL NIGHT

## DAY 1 TUESDAY 17TH MAY 2022

11:30 Welcome and Faculty Session 1 Opening Remarks

11.45-12.30 Su Heinzel

12:30-13:15 LUNCH

13.15-15.30 Faculty Session I

Chair: Rehana Hewavisenti

13.15-14.00 Georgina Clark

14.00-15.30 Shalin Naik (Technology Talk)

15:30-16:00 BREAK

16.00-16.05 Abcam

16.05-18.05

Participant session I Chair: Daryan Kempe

Move into rooms

18.30 - 19.30 DINNER

19.30 - SOCIAL NIGHT Meet & Greet



#### BREAKFAST

8.50-10.20 Faculty Session IV Chair: Rhiane Moody

8:50-9.35 Anselm Enders

9.35-10.20 Connie Jackaman

10.20-10.25 Millennium Science - 10x Genomics

#### 10:30-11:00 BREAK

**11.00-12.30 Faculty Session V** Chair: Francesca McGrath

11.00-11.45 Andy Flies

11.45-12.30 Lisa Ebert

12:30-13:30 LUNCH

**13.30-15.30 Participant session IV** Chair: Sophie Curio

#### 15:30-16:00 BREAK

16.00-16.45 Faculty Session VI Chair: Zhijia Yu

16.00-16.45 Iain Comerford

16.45- 18.15 Professional skills workshop

The art of reviewing, writing and grantsmanship. J. Reed, A. Flies, K. Schroder.

18.30 - 19.30 DINNER

19.30 - SOCIAL NIGHT



#### BREAKFAST

9.00-10.30 Faculty Session VII Chair: Timothy Patton

9.00-9.45 Chris Engwerda

9.45-10.30 Michelle Wykes

10:30-11:00 BREAK

11.00-12.30 Faculty Session VIII

11.00-11.45 Katherine Kedzierska

11.45-12.30 Jo Reed

12.30-13.00 CLOSING & PRIZES

13.30 Departure

## **PARTICIPANT SESSIONS** ORAL PRESENTATIONS

## SESSION I

#### Tuesday 16.05-18.05

Debbie Burnett	16:05	15min
Timothy Patton	16:20	9min
Jeniffer Loaiza	16:29	9min
Liam Kealy	16:38	9min
Yanran Zhao	16:47	9min
BREAK	16:56	9min
Zhijia Yu	17:05	9min
Etienne Masle-Farquhar	17:14	9min
Francesca McGrath	17:23	9min
Joseph Mackie	17:32	9min
Nadya Panagides	17:41	9min
Lauren Stern	17:50	9min

#### **SESSION II**

#### Wed 11-12.30

Sandali Seneviratne	11:00	9min
Peter Cuthbertson	11:09	9min
Christopher Jara	11:18	9min
Jennifer Stables	11:27	9min
Katherine Balka	11:36	9min
Shanna Hosking	11:45	9min
Rehana Hewavisenti	11:54	9min
Sarah Dart	12:03	9min
Jack Polmear	12:12	9min

## **SESSION III**

#### Wed 15.30-16.30

15:30	9min
15:39	9min
15:48	9min
15:57	9min
16:06	9min
16:15	9min
	15:30 15:39 15:48 15:57 16:06 16:15

## **SESSION IV**

#### Thur 13.30-15.30

Ee Shan Pang	13:30	15min
Eric Alves	13:45	9min
Madeleine Wemyss	13:54	9min
Leslie Dominguez Cadena	14:03	9min
Alana Whitcombe	14:12	9min
BREAK	14:21	9min
Diana Quan	14:30	9min
Jacinta Smith	14:39	9min
Rhiannon Bolton	14:48	9min
Emily Bryan	14:57	9min
Rebecca Buckland	15:06	9min
Cassandra Harapas	15:15	9min

## **Recombinant** antibodies **Infinitely better**



#### Recombinant antibody advantages

- Highest level of consistency and unrivaled reproducibility
- Improved sensitivity and confirmed specificity
- Ease of scalability and continuity of supply
- High-throughput in vitro manufacture

Find out more at www.abcam.com/recombinant or scan the QR code



Learn more



AU N7

Phone: 0800 758 929 Ordering: nz.orders@abcam.com Technical: nz.technical@abcam.com

Phone: 1800 960 553 Ordering: au.orders@abcam.com Technical: au.technical@abcam.com

















O

**Bioactive proteins** 

KO cell lines & lysates

ELISA kits. HC/ICC kits

Cellular assays

Buffers and ancillary reagents

Custom services



# Redefine immunology with multiomic single cell and spatial characterisation



## Download eBook

## **Single Cell Immune Profiling**

Analyse full length paired BCRs/TCRs, surface protein expression, antigen specificity, and 5' gene expression in the same cell

## **Single Cell Gene Expression**

Profile cell types and states with 3' gene expression, surface protein expression, and CRISPR perturbations in the same cell

## **Spatial Gene Expression**

Spatially profile gene expression with morphological context in intact FFPE or fresh frozen tissue samples

## Single Cell Multiome ATAC + Gene Expression

Explore combined gene expression and chromatin accessibility data from the same cell to uncover gene regulatory patterns





1800 678 242

sales@mscience.com.au



www.mscience.com.au

@mscienceaustnz

# **SPONSORS**

**Platinum Sponsor** 

## abcam

#### **Major Sponsors**



science

Distributed by







#### **Supporting Sponsors**

MONASH BIOMEDICINE DISCOVERY INSTITUTE



THE JOHN CURTIN SCHOOL OF MEDICAL RESEARCH







## ORGANISING COMMITTEE

## **CHAIRS**

Su Heinzel Walter and Eliza Hall Institute heinzel@wehi.edu.au

Joanne Reed Westmead Institute for Medical Research joanne.reed@sydney.edu.au

#### **SPONSORSHIP**

Ee Shan Pang Monash University eeshan.pang@monash.edu

#### **PROJECT MANAGER**

Deborah Burnett Garvan Institute of Medical Research d.burnett@garvan.org.au

### **ASI GENERAL MANAGER**

Tyani Chan generalmanager@immunology.org.au

## **DELEGATE** SUB COMMITTEE

We thank the following delegates for their contributions in helping us organise AIS-2!

#### TRANSPORTATION

Jacinta Smith Diana Quan

#### SOCIAL

Leslie Dominguez Cadena Alexandra Dvorscek Timothy Patton Nicola Principe Zhijia Yu

#### CATERING

Joseph Mackie Francesca McGrath

## SOCIAL MEDIA & PHOTOGRAPHY

Sophie Curio Madeleine Wemyss

#### AV

Gemma Hartley

## **ROOM ALLOCATION**

Emily Bryan



## www.immunology.org.au